Thoracoscopic Resection of Fluorodeoxyglucose-Avid Mediastinal Lymph Nodes Associated with Advanced Ovarian Carcinoma

Masatsugu Hamaji; Ken Yamaguchi; Sho Koyasu; Hiroshi Date

doi:10.1055/s-0038-1667325

The Thoracic and Cardiovascular Surgeon, Table of Contents

Thorac Cardiovasc Surg 2019; 67(08): 692-696
DOI: 10.1055/s-0038-1667325

Short Communication

Georg Thieme Verlag KG Stuttgart · New York

Thoracoscopic Resection of Fluorodeoxyglucose-Avid Mediastinal Lymph Nodes Associated with Advanced Ovarian Carcinoma

Masatsugu Hamaji

¹Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan

,

Ken Yamaguchi

²Department of Obstetrics and Gynecology, Kyoto University Hospital, Kyoto, Japan

,

Sho Koyasu

³Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Hospital, Kyoto, Japan

,

Hiroshi Date

¹Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan

› Author Affiliations

Abstract

All articles of this category

Abstract

The indication for surgery is controversial in patients with advanced ovarian cancer and fluorodeoxyglucose (FDG)-avid mediastinal lymph nodes. Herein we report our experience in thoracoscopic resection of FDG-avid mediastinal lymph nodes associated with advanced ovarian cancer in six patients. No perioperative or long-term mortality was noted. FDG-avid mediastinal lymph nodes in advanced ovarian carcinoma may merit thoracoscopic resection with histological confirmation for more precise staging.

Keywords

ovarian carcinoma - mediastinal lymph nodes - thoracoscopy/VATS

Full Text

References

References
1 Hynninen J, Kemppainen J, Lavonius M. , et al. A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer. Gynecol Oncol 2013; 131 (02) 389-394
2 Bats AS, Hugonnet F, Huchon C. , et al. Prognostic significance of mediastinal 18F-FDG uptake in PET/CT in advanced ovarian cancer. Eur J Nucl Med Mol Imaging 2012; 39 (03) 474-480
3 Hynninen J, Auranen A, Carpén O. , et al. FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread. Gynecol Oncol 2012; 126 (01) 64-68
4 Winter III WE, Maxwell GL, Tian C. , et al; Gynecologic Oncology Group Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2008; 26 (01) 83-89
5 Tian WJ, Chi DS, Sehouli J. , et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol 2012; 19 (02) 597-604
6 Forstner R, Sala E, Kinkel K, Spencer JA. ; European Society of Urogenital Radiology. ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol 2010; 20 (12) 2773-2780
7 Perri T, Ben-Baruch G, Kalfon S. , et al. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?. Gynecol Oncol 2013; 131 (01) 27-31
8 Signorelli M, Guerra L, Pirovano C. , et al. Detection of nodal metastases by 18F-FDG PET/CT in apparent early stage ovarian cancer: a prospective study. Gynecol Oncol 2013; 131 (02) 395-399